Utibe R Essien1, Jared W Magnani2, Nemin Chen3, Walid F Gellad4, Michael J Fine4, Inmaculada Hernandez5. 1. Division of General Internal Medicine, University of Pittsburgh School of Medicine, Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. Electronic address: uessien@pitt.edu. 2. Department of Medicine, Division of Cardiology, Heart and Vascular Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 3. Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA. 4. Division of General Internal Medicine, University of Pittsburgh School of Medicine, Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA. 5. Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with a 5-fold increased risk of ischemic stroke. Racial/ethnic minorities and women with AF have higher rates of stroke compared to white individuals and men respectively. Oral anticoagulation reduces the risk of stroke, yet prior research has described racial/ethnic and sex-based variation in its use. We sought to examine the initiation of any oral anticoagulant (warfarin or direct-acting oral anticoagulants, DOACs) by race/ethnicity and sex in patients with incident, non-valvular AF. Further in those who initiated any anticoagulant, we examined DOAC vs. warfarin initiation by race/ethnicity and sex. METHODS: We used claims data from a 5% sample of Medicare beneficiaries to identify patients with incident AF from 2012 to 2014, excluding those without continuous Medicare enrollment. We used logistic regression to assess the association between race/ethnicity (white, black, Hispanic), sex, and oral anticoagulant initiation (any, warfarin vs. DOAC), adjusting for sociodemographics, medical comorbidities, stroke and bleeding risk. RESULTS: The cohort of 42,952 patients with AF included 17,935 women, 3282 blacks, and 1958 Hispanics. Overall OAC initiation was low (49.2% whites, 48.1% blacks, 47.5% Hispanics, 48.1% men, and 51.5% women). After adjusting, blacks (odds ratio (OR) 0.84; 95% CI, 0.78-0.91) were less likely than whites to initiate any oral anticoagulant with no difference observed between Hispanics and whites (OR 0.92; 95% CI, 0.83-1.01). Women were less likely than men to initiate any oral anticoagulant, OR 0.59 (95% CI 0.55-0.64). Among initiators of oral anticoagulation, DOAC use was low (35.8% whites, 29.3% blacks, 40.0% Hispanics, 41.6% men, and 42.4% women). After adjusting, blacks were less likely to initiate DOACs than whites, OR 0.75 (95% CI 0.66-0.85); the odds of DOAC initiation did not differ between Hispanic and white patients or between men and women. CONCLUSION: In a national cohort of Medicare beneficiaries with newly-diagnosed AF, overall oral anticoagulant initiation was lower in blacks and women, with no difference observed by Hispanic ethnicity. Among oral anticoagulant initiators, blacks were less likely to initiate novel DOACs, with no differences identified by Hispanic ethnicity or sex. Identifying modifiable causes of treatment disparities is needed to improve quality of care for all patients with AF. Published by Elsevier Inc.
BACKGROUND:Atrial fibrillation (AF) is the most common heart rhythm disorder and is associated with a 5-fold increased risk of ischemic stroke. Racial/ethnic minorities and women with AF have higher rates of stroke compared to white individuals and men respectively. Oral anticoagulation reduces the risk of stroke, yet prior research has described racial/ethnic and sex-based variation in its use. We sought to examine the initiation of any oral anticoagulant (warfarin or direct-acting oral anticoagulants, DOACs) by race/ethnicity and sex in patients with incident, non-valvular AF. Further in those who initiated any anticoagulant, we examined DOAC vs. warfarin initiation by race/ethnicity and sex. METHODS: We used claims data from a 5% sample of Medicare beneficiaries to identify patients with incident AF from 2012 to 2014, excluding those without continuous Medicare enrollment. We used logistic regression to assess the association between race/ethnicity (white, black, Hispanic), sex, and oral anticoagulant initiation (any, warfarin vs. DOAC), adjusting for sociodemographics, medical comorbidities, stroke and bleeding risk. RESULTS: The cohort of 42,952 patients with AF included 17,935 women, 3282 blacks, and 1958 Hispanics. Overall OAC initiation was low (49.2% whites, 48.1% blacks, 47.5% Hispanics, 48.1% men, and 51.5% women). After adjusting, blacks (odds ratio (OR) 0.84; 95% CI, 0.78-0.91) were less likely than whites to initiate any oral anticoagulant with no difference observed between Hispanics and whites (OR 0.92; 95% CI, 0.83-1.01). Women were less likely than men to initiate any oral anticoagulant, OR 0.59 (95% CI 0.55-0.64). Among initiators of oral anticoagulation, DOAC use was low (35.8% whites, 29.3% blacks, 40.0% Hispanics, 41.6% men, and 42.4% women). After adjusting, blacks were less likely to initiate DOACs than whites, OR 0.75 (95% CI 0.66-0.85); the odds of DOAC initiation did not differ between Hispanic and white patients or between men and women. CONCLUSION: In a national cohort of Medicare beneficiaries with newly-diagnosed AF, overall oral anticoagulant initiation was lower in blacks and women, with no difference observed by Hispanic ethnicity. Among oral anticoagulant initiators, blacks were less likely to initiate novel DOACs, with no differences identified by Hispanic ethnicity or sex. Identifying modifiable causes of treatment disparities is needed to improve quality of care for all patients with AF. Published by Elsevier Inc.
Authors: Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip Journal: Chest Date: 2010-03-18 Impact factor: 9.410
Authors: Utibe R Essien; DaJuanicia N Holmes; Larry R Jackson; Gregg C Fonarow; Kenneth W Mahaffey; James A Reiffel; Benjamin A Steinberg; Larry A Allen; Paul S Chan; James V Freeman; Rosalia G Blanco; Karen S Pieper; Jonathan P Piccini; Eric D Peterson; Daniel E Singer Journal: JAMA Cardiol Date: 2018-12-01 Impact factor: 14.676
Authors: Jonathan P Piccini; Haolin Xu; Margueritte Cox; Roland A Matsouaka; Gregg C Fonarow; Javed Butler; Anne B Curtis; Nihar Desai; Margaret Fang; Pamela J McCabe; Robert L Page Ii; Mintu Turakhia; Andrea M Russo; Bradley P Knight; Mandeep Sidhu; Jodie L Hurwitz; Kenneth A Ellenbogen; William R Lewis Journal: Circulation Date: 2019-03-19 Impact factor: 29.690
Authors: Harsh Golwala; Larry R Jackson; DaJuanicia N Simon; Jonathan P Piccini; Bernard Gersh; Alan S Go; Elaine M Hylek; Peter R Kowey; Kenneth W Mahaffey; Laine Thomas; Gregg C Fonarow; Eric D Peterson; Kevin L Thomas Journal: Am Heart J Date: 2015-12-30 Impact factor: 4.749
Authors: Eric Shulman; Jay J Chudow; Utibe R Essien; Anusha Shanbhag; Faraj Kargoli; Jorge Romero; Luigi Di Biase; John Fisher; Andrew Krumerman; Kevin J Ferrick Journal: Int J Cardiol Date: 2018-10-10 Impact factor: 4.164
Authors: Ying Xian; Haolin Xu; Emily C O'Brien; Shreyansh Shah; Laine Thomas; Michael J Pencina; Gregg C Fonarow; DaiWai M Olson; Lee H Schwamm; Deepak L Bhatt; Eric E Smith; Deidre Hannah; Lesley Maisch; Barbara L Lytle; Eric D Peterson; Adrian F Hernandez Journal: JAMA Neurol Date: 2019-10-01 Impact factor: 18.302
Authors: Annie McDermott; Nadejda Kim; Leslie R M Hausmann; Jared W Magnani; Chester B Good; Terrence M A Litam; Maria K Mor; Toluwa D Omole; Walid F Gellad; Michael J Fine; Utibe R Essien Journal: J Gen Intern Med Date: 2022-09-23 Impact factor: 6.473
Authors: Faye L Norby; Pamela L Lutsey; Nathan D Shippee; Lin Y Chen; Carrie Henning-Smith; Alvaro Alonso; Rob F Walker; Aaron R Folsom Journal: Am J Cardiovasc Drugs Date: 2021-10-11 Impact factor: 3.283
Authors: Raisa L Silva; Emily N Guhl; Andrew D Althouse; Brandon Herbert; Michael Sharbaugh; Utibe R Essien; Leslie R M Hausmann; Jared W Magnani Journal: Am J Prev Cardiol Date: 2021-09-03
Authors: Jing Luo; Robert Feldman; Scott Rothenberger; Mary Korytkowski; Michael A Fischer; Walid F Gellad Journal: J Gen Intern Med Date: 2022-01-19 Impact factor: 6.473
Authors: Utibe R Essien; Jelena Kornej; Amber E Johnson; Lucy B Schulson; Emelia J Benjamin; Jared W Magnani Journal: Nat Rev Cardiol Date: 2021-06-02 Impact factor: 32.419
Authors: Utibe R Essien; Nadejda Kim; Leslie R M Hausmann; Maria K Mor; Chester B Good; Jared W Magnani; Terrence M A Litam; Walid F Gellad; Michael J Fine Journal: JAMA Netw Open Date: 2021-07-01